Research advances in influencing factors for natural prognosis of patients with chronic HBV infection in immune tolerance phase

• Main Authors: GAO Hongyan, LIU Na, LI Chunxia
• Format: Article
• Language: zho
• Published: Editorial Department of Journal of Clinical Hepatology 2017-08-01
• Series: Linchuang Gandanbing Zazhi
• Online Access: http://www.lcgdbzz.org/qk_content.asp?id=8398

In the natural history of chronic HBV infection, immune tolerance phase is the early stage of disease progression and plays a decisive role in disease monitoring and treatment. The latest CHB guidelines in China and foreign countries recommend regular follow-up for patients in immune tolerance phase, instead of antiviral therapy. Although patients with chronic HBV infection in immune tolerance phase tend to have a good prognosis, they may also have the risk of progression to end-stage liver diseases such as liver cirrhosis, hepatocellular carcinoma, and liver function decompensation. This article elaborates on the influencing factors for natural prognosis of patients with chronic HBV infection in immune tolerance phase and provides a theoretical basis for clinical judgment of patient′s conditions, determination of the most appropriate timing for the initiation of antiviral therapy, and individualized management.